Predictors of perirenal haematoma post-percutaneous ultrasound-guided renal biopsy

Shihao Xu¹, Bing Xiong¹, Saifeng Lin¹, Qiao Li¹, Lei Wang² and Wenjie Zhao¹

Abstract

Objective: To perform a prospective study to determine the risk factors associated with perirenal haematoma development after percutaneous renal biopsy (PRB).

Methods: This multivariate prospective study collected demographic and clinical data from all consecutive adult patients that underwent real-time ultrasound-guided PRB of native kidneys. All biopsies were performed by two well-trained ultrasound physicians using 16G biopsy needles. Routine renal ultrasounds were performed within 12–24 h after biopsies in order to observe post-biopsy perirenal haematoma formation. Patients were stratified based on the occurrence of post-biopsy haematoma development.

Results: This prospective study enrolled 218 patients and stratified them into a haematoma group (n = 126) and a non-haematoma group (n = 92). Binary logistic regression analysis identified female patients (odds ratio [OR] 1.990; 95% confidence interval [CI] 1.125, 3.521), patients with a body mass index (BMI) ≥ 28 kg/m² (OR 2.660; 95% CI 1.097, 6.449) and patients with immediate post-biopsy active bleeding (IPAB) (OR 2.572; 95% CI 1.422, 4.655) as being more likely to have perirenal haematoma after real-time ultrasound guided PRB of native kidneys.

Conclusion: Female sex, a BMI ≥ 28 kg/m² and IPAB were risk factors for perirenal haematoma after real-time ultrasound-guided PRB of native kidneys.

Keywords

Percutaneous renal biopsy, perirenal haematoma, immediate post-biopsy active bleeding, body mass index, sex

Date received: 20 June 2021; accepted: 15 October 2021
Introduction

Iversen and Brun were the first to report a successful renal biopsy in 1951. At present, percutaneous renal biopsy (PRB) is considered a low-risk procedure and an essential technique that can provide important information to nephrologists during patient evaluation, research and clinical practice. Development of ultrasound imaging technology and the application of automatic biopsy needles have resulted in a low occurrence of complications after renal biopsy. In particular, the rate of serious complications, such as a need for angiographic intervention, nephrectomy or death, is < 1%. However, bleeding complications do occur and the incidence was up to 30% or more in some research. With improving social awareness, patients expect reduced procedure-related complications and costs, without compromising the results. Therefore, a successful PRB should not only ensure that sufficient material for an adequate diagnosis is obtained, but it should also minimize possible complications. Factors contributing to perirenal haematoma after PRB need to be identified. It is very important to determine which patients will develop a perirenal haematoma after performing PRB of native kidneys.

Many factors are related to the formation of haematoma after PRB. Previous studies have reached different conclusions. One study reported that elevated creatinine and baseline blood pressure were associated with bleeding after PRB. Another study found that inpatient status and thrombocytopenia were the only significant risk factors for complications. In another large retrospective study, low platelet count was reported to be the most important single risk factor in predicting bleeding post PRB. Currently, which factors are related to the occurrence of perirenal haematoma after PRB remains controversial.

The objective of this research was to assess the factors that have a relationship with the incidence of perirenal haematoma after PRB in a prospective cohort of patients that underwent real-time ultrasound-guided automated PRB of native kidneys in a single ultrasonography centre.

Patients and methods

Patient population

This prospective study enrolled all consecutive adult patients that underwent real-time ultrasound-guided percutaneous native renal biopsy at the Department of Ultrasonography, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China, between August 2016 and April 2017. All patient details have been de-identified. All biopsies were taken by two well-trained ultrasound physicians that conduct >1000 biopsies each year (S.X. & Q.L.). In this current study, the nephrologists decided the indications for PRB and it was indicated due to the need for diagnosis in the following situations: nephrotic syndrome, nephritic syndrome, renal failure of unknown aetiology, asymptomatic urinary abnormalities. Paediatric patients, transplant kidney biopsies, kidney neoplasms biopsies, solitary kidney, abnormal kidney anatomy and patients with abnormal coagulation parameters were all excluded. The reporting of this study conforms with STROBE guidelines.

This study was approved by the Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University (no. YJ2016-061-01; 2016.6.6). All patients provided written informed consent.

Data collection

The following information was analysed for each patient before the procedure: age, sex, height, weight, serum creatinine (SCr), blood urea nitrogen (BUN), uric acid, haemoglobin (Hb), platelet count, history of
hypertension, history of diabetes mellitus, estimated glomerular filtration rate (eGFR; using the Modification of Diet in Renal Disease formula), kidney function was determined using an abbreviated equation developed using data from the Modification of Diet in Renal Disease study to estimate glomerular filtration rate), 24-h urinary protein, total cholesterol, triglyceride, low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C). The SCr, Bun, uric acid, 24-h urinary protein, total cholesterol, triglyceride, LDL-C and HDL-C were measured using an AU5800 Series Clinical Automatic Chemistry Analyzer (Beckman, Shanghai, China). The Hb and platelet count were measured using a BC6800 Series Automatic blood cell analyzer (Mindray, Shenzhen, China). Information collected at the time of biopsy included systolic and diastolic blood pressures, peak velocity of renal artery (PVRA), peak velocity of arcuate artery (PVAA) and renal parenchymal thickness (RPT).

**Renal biopsy procedure**

Patients stopped anticoagulation therapy appropriately and antiplatelets use at least 5 days prior to the biopsy. All patients had normal prothrombin time (PTT), prothrombin activity (PTA) and international normalized ratio (INR) prior to the procedure. The systolic and diastolic arterial pressures were below 160 mmHg and 90mmHg at the time of the procedure, respectively. When perirenal haematoma was found post-biopsy, coagulation drugs or vasoconstrictors were considered for use by nephrologists.

All renal biopsies were performed in an ultrasonography laboratory using a HI VISION Ascendus ultrasound system (Hitachi Aloka Medical Ltd., Tokyo, Japan) and a C715 convex probe (1–5 MHz; Hitachi Aloka Medical Ltd.). All data were collected with the same equipment. A Tru-CoreTM II Automatic Biopsy Instrument with an MCXS2016TY biopsy needle (16G; Disposable Automatic Argon Medical Devices Inc., Plano, TX, USA) was used. Patients were positioned in the prone position with their abdomen on a firm pillow. They were required to remain still during the procedure. The left kidney or right kidney was selected randomly by tossing coins. The lower lateral pole of the kidney was selected for biopsy. After location, the place of needle insertion was marked on the skin. Routine sterilization and draping were performed. The probe was covered with a sterile cover and sterile jelly applied. The operator conducted the procedure with the left hand holding the ultrasound probe and the right hand holding the biopsy gun. A solution of 2% lidocaine was injected under real-time ultrasound guidance from the target skin to the renal capsule. When the biopsy needle reached the lower pole of the kidney capsule, the patient was told to hold their breath. The biopsy gun was fired and the needle tip was confirmed in the kidney. Then the biopsy needle was removed quickly from the kidney. Two cores of renal tissue were obtained to ensure an adequate sample for diagnosis. After the procedure, Doppler ultrasonography was routinely performed immediately to observe any signs of active bleeding (Figure 1). The occurrence of bleeding was recorded for each patient.

**Post-biopsy evaluation of complications**

Following the PRB, a bandage was applied to the flank and the patient was required to lay in bed flat on their back for 6h. They then remained in bed for 24h in the nephrology ward. Routine renal ultrasounds were performed within 12–24h after biopsies to observe any perirenal haematoma formation (Figure 2). Other outcomes due to the renal biopsy were recorded including embolization, surgery or death.
Statistical analyses

All statistical analyses were performed using IBM SPSS Statistics for Windows, Version 20.0 (IBM Corp., Armonk, NY, USA). Data are presented as mean ± SD, median (interquartile range) or absolute frequency. χ²-test was used to compare categorical data. Student’s t-test was used to compare continuous data. Binary logistic regression analysis was used to determine the effect of various factors on the formation of haematoma. The factors included in this analysis were sex, age, body mass index (BMI), SCr, BUN, uric acid, Hb, platelet count, history of hypertension, history of diabetes mellitus, eGFR, 24-h urinary protein, total cholesterol, triglyceride, LDL-C, HDL-C, PVRA, PVAA, immediate post-biopsy active bleeding (IPAB) and RPT. A P-value <0.05 was considered statistically significant.

Results

This prospective study enrolled 218 patients that underwent real-time ultrasound-guided automated PRB of native kidneys. Demographic and clinical characteristics of the overall study cohort are shown in Table 1. The mean ± SD BMI of the patients was 24.30 ± 3.71 kg/m² (range, 16.45–39.26 kg/m²). There were 109 of 218 (50.0%) patients with a BMI ≥24 kg/m² and 31 of 218 (14.2%) patients had a BMI
The platelet counts of most patients were in the normal range (125–350 \(10^9/l\)), while only nine patients had platelet counts < 125 \(10^9/l\). The patients were stratified according to the occurrence of post-biopsy haematoma \((n = 126)\) and the clinical and demographic data for the two groups are presented in Tables 2 and 3. There were no significant differences between the haematoma and non-haematoma groups in terms of age, SCr, BUN, uric acid, total cholesterol, triglyceride, HDL-C, LDL-C, Hb, PVRA, PVAA, eGFR, RPT, 24-h urinary protein and platelet count. There were no significant differences in history of hypertension or history of diabetes mellitus between the haematoma and non-haematoma groups. There were significant differences in IPAB \((P = 0.004)\) and BMI \((P = 0.046)\) between the haematoma and non-haematoma groups. In the sex comparison between the two groups, the non-significant \(P\)-value \((P = 0.069)\) was close to 0.05 so sex was also included in the binary logistic regression analysis. The binary logistic regression analysis found that BMI, IPAB and sex had a statistical relationship with the occurrence of perirenal haematoma after PRB (Table 4).

Perirenal haematoma was the only complication observed. There were no occurrences of embolization, surgery or death due to the biopsy.

### Discussion

Most of the published studies about bleeding complications after percutaneous ultrasound-guided renal biopsy were retrospective analyses,\(^2\) while this current study was a multivariate prospective analysis. In this current study, all biopsies were performed by only two sonographers and all biopsy needles were 16G. This helped to avoid the impact of different operators (variable experience) or different types of biopsy needles when analysing the risk factors for post-biopsy complications.
**Table 2.** Baseline continuous demographic and clinical data of patients \((n = 218)\) that underwent real-time ultrasound-guided automated percutaneous renal biopsy of native kidney stratified according to the development of post-biopsy haematoma.

| Characteristic                  | Non-haematoma group \(n = 92\) | Haematoma group \(n = 126\) |
|--------------------------------|---------------------------------|-----------------------------|
| Age, years                     | 46.66 ± 14.83                  | 44.92 ± 13.74               |
| SCr, \(\mu\)mol/l              | 109.86 ± 102.84                | 139.59 ± 190.87             |
| BUN, mmol/l                    | 6.84 ± 3.26                    | 7.23 ± 5.45                 |
| Uric acid, \(\mu\)mol/l        | 387.47 ± 94.32                 | 375.44 ± 90.74              |
| Total cholesterol, mmol/l       | 6.09 ± 2.44                    | 6.42 ± 2.47                 |
| Triglyceride, mmol/l            | 2.56 ± 2.53                    | 2.62 ± 2.11                 |
| HDL-C, mmol/l                  | 1.15 ± 0.35                    | 1.23 ± 0.46                 |
| LDL-C, mmol/l                  | 3.42 ± 1.59                    | 3.75 ± 1.94                 |
| Hb, g/l                        | 126.81 ± 24.08                 | 124.38 ± 23.52              |
| PVRA, cm/s                      | 79.69 ± 29.17                  | 77.70 ± 29.23               |
| PVAA, cm/s                      | 25.49 ± 10.66                  | 25.12 ± 10.59               |
| eGFR, ml/min/1.73 m²            | 82.94 ± 31.27                  | 81.10 ± 35.26               |
| RPT, mm                         | 6.92 ± 1.53                    | 7.07 ± 1.51                 |
| 24-h urinary protein, mg/dl     | 300.08 ± 482.20                | 296.95 ± 503.88             |
| Platelet count, \(\times 10^9\)/l| 246.43 ± 72.96                 | 240.98 ± 74.41              |

Data presented as mean ± SD.
No significant between-group differences \((P ≥ 0.05)\); continuous data compared with Student’s t-test.
SCr, serum creatinine; BUN, blood urea nitrogen; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Hb, haemoglobin; PVRA, peak velocity of renal artery; PVAA, peak velocity of arcuate artery; eGFR, estimated glomerular filtration rate; RPT, renal parenchymal thickness.

**Table 3.** Baseline categorical demographic and clinical data of patients \((n = 218)\) that underwent real-time ultrasound-guided automated percutaneous renal biopsy of native kidney stratified according to the development of post-biopsy haematoma.

| Characteristic                  | Non-haematoma group \(n = 92\) | Haematoma group \(n = 126\) | Statistical analyses\(^a\) |
|--------------------------------|---------------------------------|-----------------------------|--------------------------|
| History of hypertension        | Yes 39                          | 63                          | NS                       |
|                                | No 53                           | 63                          |                          |
| History of diabetes mellitus   | Yes 13                          | 15                          | NS                       |
|                                | No 79                           | 111                         |                          |
| BMI, kg/m²\(^2\)               | ≥28 8                           | 23                          | \(P = 0.046\)            |
|                                | <28 84                          | 103                         |                          |
| Sex                            | Female 41                       | 73                          | NS                       |
|                                | Male 51                         | 53                          |                          |
| IPAB                           | Yes 25                          | 60                          | \(P = 0.004\)            |
|                                | No 67                           | 66                          |                          |

Data presented as \(n\) of patients.
\(^a\)Categorical data compared with \(\chi^2\)-test; NS, no significant between-group difference \((P ≥ 0.05)\).
BMI, body mass index; IPAB, immediate post-biopsy active bleeding.
haematoma. Twenty potential risk factors were included in this current study, including haemodynamic factors that were analysed for the first time to the best of our knowledge.

Perirenal haematoma occurred in 126 of 218 (57.8%) patients after PRB in the current study. This would appear to be a high rate, but it was reasonable. First, a post-biopsy ultrasound examination was carried out for every patient that underwent PRB in this current study, whereas in other research, an ultrasound examination was only carried out for patients with symptoms.23 Secondly, the rate of perirenal haematoma is highly associated with the timing of the post-biopsy ultrasound examination. For example, a previous study demonstrated that only 6% of biopsies had haematoma when an ultrasound examination was carried out immediately after the PRB.24 Whereas, another study found that 32% of patients had a haematoma when the ultrasound examination was carried out 7–8 h after the PRB.25 When the ultrasound examination was carried out 18 h after the PRB, 37.8% of patients had a haematoma.13 If the ultrasound examination or a computerized tomography scan were undertaken at 24–72 h after the PRB, 70% to >90% of patients experienced a haematoma.26,27 In this current study, the ultrasound examination was performed 12–24 h, so a rate of post-biopsy haematoma of 57.8% would appear to be acceptable. Thirdly, the mean ± SD BMI of the patients was 24.30 ± 3.71 kg/m² in the current study (range, 16.45–39.26 kg/m²).

There were 109 of 218 (50.0%) patients with a BMI ≥ 24 kg/m² and 31 of 218 (14.2%) patients had a BMI ≥ 28 kg/m² in the current study. Previously, body weight was found to be associated with a higher risk of bleeding complications after PRB, which was similar to the current results based on BMI.28 The probability of perirenal haematoma in obese patients (BMI ≥ 28 kg/m²) was 2.66-times the nonobese patients after renal biopsy (Table 4).

Previous research has demonstrated that post-biopsy bleeding was related to sex and age.15 The current study also found that post-biopsy bleeding was related to sex, but the findings did not support the view that post-biopsy bleeding was related to age. Female patients were 1.99-times more likely to develop post-biopsy haematoma after PRB than male patients (Table 4). Other research has found no statistical association between bleeding complications and age and sex.21 The same study also found that the platelet count prior to the renal biopsy was highly predictive of symptomatic haematoma, but there were no statistical associations between bleeding complications and uncontrolled hypertension, Hb, INR and PTT.21 In contrast, there was no statistical association between perirenal haematoma and platelet count in the current study, which might have been because the platelet count in the majority of patients was in the normal range (range, 125–350 × 10⁹/l). Only nine patients had platelet counts < 125 × 10⁹/l. It should be noted that the objective of the current

**Table 4.** Binary logistic regression analysis of factors associated with the perirenal haematoma after percutaneous renal biopsy of native kidney.

| Risk factor                  | OR   | 95% CI          | P-value |
|-----------------------------|------|-----------------|---------|
| BMI, ≥ 28 versus < 28 kg/m² | 2.660| 1.097, 6.449    | P = 0.030 |
| IPAB, yes versus no         | 2.572| 1.422, 4.655    | P = 0.002 |
| Sex, female versus male     | 1.990| 1.125, 3.521    | P = 0.018 |

OR, odds ratio; CI, confidence interval; BMI, body mass index; IPAB, immediate post-biopsy active bleeding.
study was different to that of the previous study.21 The current study focused on the relationship between all post-PRB haematomas and platelet counts, whereas the previous study focused on the relationship between symptomatic haematomas and platelet counts.21 In consideration of the fact that coagulability as a major influencing factor for bleeding after invasive procedures, all patients in the current study had normal PTT, PTA and INR values prior to the PRB. Therefore, the relationship between INR, PTT and post-biopsy perirenal haematoma could not be investigated in the current study. Consistent with their findings,21 the current study also found no statistical relationship between perirenal haematoma and Hb. However, some previous research demonstrated that a lower pre-biopsy Hb level was associated with a higher risk of complications.10,29

In terms of the relationship between blood pressure and post-biopsy perirenal haematoma, a range of different findings have been reported. For example, research has shown that the predictive characteristics of any complication (minor or major) were systolic blood pressure $\geq 170$ mm Hg, bleeding time $>7.5$ min and SCr $>3.5$ mg/dl.30 Arterial hypertension was found to double the bleeding risk in an analysis of 462 biopsies.31 Similar results were published by the Norwegian registry on 8573 biopsies.32 Nevertheless, there were studies that did not confirm this association,33,34 emphasizing that the history of hypertension was a factor and not the present blood pressure. The risk of bleeding was increased in patients with a history of hypertension, irrespective of blood pressure at the time of biopsy.19 It is possible that arteriolar hyalinosis associated with chronic hypertension limits the ability of vessels to contract following renal biopsy, regardless of the current blood pressure.23 As blood pressure at the time of the renal biopsy could be related to a range of factors such as nervousness and apprehension, not having a good night’s sleep the night before the biopsy, infusion quantity and environmental factors, the current study recorded the history of hypertension; and required that the systolic and diastolic arterial pressures were $<160$ and $<90$ mmHg at the time of the procedure, respectively. The current study found that a history of hypertension had no statistical relationship with post-biopsy renal haematoma.

Traditionally, a history of diabetes mellitus and hyperlipidaemia might have an impact on blood vessels, especially the arterial blood vessels. Therefore, they could be risk factors for the occurrence of haematoma after renal biopsy. To investigate this possibility, the current study collected data on a history of diabetes mellitus, total cholesterol, triglyceride, LDL-C and HDL-C from each study participant. The analyses demonstrated that a history of diabetes mellitus, total cholesterol, triglyceride, LDL-C and HDL-C had no relationship with the development of post-biopsy perirenal haematoma. It should be noted that only 28 of 218 patients (12.8%) had diabetes mellitus in the current study, which may have impacted on the results.

Higher SCr and acute renal insufficiency were significant confounding factors in biopsy complications in a large multicentre study on 2563 patients.35 Data related to renal function were also collected in the current study including SCr, BUN, uric acid, 24-h urinary protein and eGFR. None of these factors were associated with the occurrence of post-biopsy perirenal haematoma. RPT was also recorded and it had no relationship with post-biopsy perirenal haematoma. It is inevitable that during the process of taking a kidney biopsy some blood vessels of the kidney will be damaged, especially the arterial vessels. It was surmised that renal haemodynamic parameters might have an impact on the formation of post-biopsy perirenal haematoma, so the
current study analysed the kidney-related haemodynamic parameters PVRA and PVAA. There was no relationship between PVRA, PVAA and the formation of perirenal haematoma after biopsy.

In some patients in the current study, colour Doppler ultrasonography identified a stream of blood flow along the needle path towards the ultrasound probe after the puncture needle was withdrawn from the kidney. This was defined as IPAB and it was associated with the occurrence of post-biopsy perirenal haematoma. The risk of post-biopsy perirenal haematoma in patients with IPAB was 2.57-times that of patients without active bleeding after biopsy (Table 4).

This current study had several limitations. First, the sample size was not large enough to accurately reflect the overall situation in the general population. Secondly, although routine ultrasonography was performed 12–24 h for all patients after the PRB, a small proportion of haematomas might have been missed. Thirdly, this was a single-centre study, which is not as reliable as a multi-centre study. Fourthly, hypertension has been found to increase the bleeding risk after renal biopsy. Some research has found that partial thromboplastin time and bleeding time predicted post-biopsy bleeding. These factors were not included in this current study. Finally, only the possibility of post-biopsy perirenal haematoma development was studied and not the size of the haematomas. As a consequence of these limitations, the clinical significance of the current findings remains relatively limited. Larger, multi-centre studies with more patients are required to confirm the risk factors for the occurrence of perirenal haematoma after PRB.

In conclusion, this prospective study of 218 patients demonstrated that female patients, patients with a BMI \( \geq 28 \text{ kg/m}^2 \) and patients with IPAB were more likely to have perirenal haematoma after real-time ultrasound-guided PRB of native kidney.

**Author contributions**

Conceived and designed the experiments: Shihao Xu and Wenjie Zhao; performed the experiments and collected the data: Qiao Li, Saifeng Lin, Shihao Xu and Wenjie Zhao; analysed the data: Lei Wang, Bing Xiong and Wenjie Zhao; wrote the manuscript: Bing Xiong and Wenjie Zhao. All authors read and approved the final version of the manuscript.

**Acknowledgements**

We are grateful to Bin Li, from the First Affiliated Hospital of Zhejiang University, for his assistance in the statistical analysis.

**Declaration of conflicting interest**

The authors declare that there are no conflicts of interest.

**Funding**

The present study was supported by Wenzhou Science and Technology Bureau (no. Y20180758).

**ORCID iD**

Wenjie Zhao [https://orcid.org/0000-0002-3775-3394](https://orcid.org/0000-0002-3775-3394)

**References**

1. Iversen P and Brun C. Aspiration biopsy of the kidney. *Am J Med* 1951; 11: 324–330.
2. Corapi KM, Chen JLT, Balk EM, et al. Bleeding complications of native kidney biopsy: a systematic review and meta-analysis. *Am J Kidney Dis* 2012; 60: 62–73.
3. Ahmed AM, Anees M, Riaz A, et al. Percutaneous renal biopsy by automated biopsy gun. *J Coll Physicians Surg Pak* 2003; 13: 263–266.
4. Backman U and Lindgren PG. Percutaneous renal biopsy with real-time ultrasonography. *Scand J Urol Nephrol* 1982; 16: 65–67.
5. Ballal SH, Nayak R, Dhanraj P, et al. Percutaneous renal biopsy: a single center experience with automated spring-loaded
“gun” type device. Clin Nephrol 1995; 44: 274–275.
6. Birnholz JC, Kasinath BS and Corwin HL. An improved technique for ultrasound guided percutaneous renal biopsy. Kidney Int 1985; 27: 80–82.
7. Burstein DM, Schwartz MM and Korbet SM. Percutaneous renal biopsy with the use of real-time ultrasound. Am J Nephrol 1991; 11: 195–200.
8. Lubbers H, Mahlke R, Haake C, et al. A new fine needle for easier, single handed, ultrasound-guided biopsies, requiring less advancing forces into solid organs. Z Gastroenterol 1993; 31: 484–485.
9. Riehl J, Maigatter S, Kierdorf H, et al. Percutaneous renal biopsy: comparison of manual and automated puncture techniques with native and transplanted kidneys. Nephrol Dial Transplant 1994; 9: 1568–1574.
10. Worth DP, Khanna SK, Ubhi CS, et al. The biopsy cut procedure for renal biopsies. Br Med J (Clin Res Ed) 1988; 296: 1603.
11. Yang CY, Lai MY, Lu CL, et al. Timing of Doppler examination for the detection of arteriovenous fistula after percutaneous renal biopsy. J Clin Ultrasound 2008; 36: 377–380.
12. Pasquariello A, Innocenti M, Batini V, et al. Theoretical calculation of optimal depth in the percutaneous native kidney biopsy to drastically reduce bleeding complications and sample inadequacy for histopathological diagnosis. Nephrol Dial Transplant 2007; 22: 3516–3520.
13. Eiro M, Katoh T and Watanabe T. Risk factors for bleeding complications in percutaneous renal biopsy. Clin Exp Nephrol 2005; 9: 40–45.
14. Whittier WL and Korbet SM. Timing of complications in percutaneous renal biopsy. J Am Soc Nephrol 2004; 15: 142–147.
15. Manno C, Strippoli GF, Arnesano L, et al. Predictors of bleeding complications in percutaneous ultrasound-guided renal biopsy. Kidney Int 2004; 66: 1570–1577.
16. Korbet SM. Percutaneous renal biopsy. Semin Nephrol 2002; 22: 254–267.
17. Christensen J, Lindequist S, Knudsen DU, et al. Ultrasound-guided renal biopsy with biopsy gun technique—efficacy and complications. Acta Radiol 1995; 36: 276–279.
18. Rollino C, Garofalo G, Roccatello D, et al. Colour-coded Doppler sonography in monitoring native kidney biopsies. Nephrol Dial Transplant 1994; 9: 1260–1263.
19. Shidham GB, Siddiqi N, Beres JA, et al. Clinical risk factors associated with bleeding after native kidney biopsy. Nephrology (Carlton) 2005; 10: 305–310.
20. Sethi I, Brier M and Dwyer A. Predicting post renal biopsy complications. Semin Dial 2013; 26: 633–635.
21. Simard-Meilleur MC, Troyanov S, Roy L, et al. Risk factors and timing of native kidney biopsy complications. Nephron Extra 2014; 4: 42–49.
22. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Int J Surg 2014; 12: 1495–1499.
23. Brachemi S and Bollee G. Renal biopsy practice: What is the gold standard? World J Nephrol 2014; 3: 287–294.
24. Doyle AJ, Gregory MC and Terreros DA. Percutaneous native renal biopsy: comparison of a 1.2-mm spring-driven system with a traditional 2-mm hand-driven system. Am J Kidney Dis 1995; 23: 498–503.
25. Fraser IR and Fairley KF. Renal biopsy as an outpatient procedure. Am J Kidney Dis 1995; 25: 876–878.
26. Ralls PW, Barakos JA, Kaptein EM, et al. Renal biopsy-related hemorrhage: frequency and comparison of CT and sonography. J Comput Assist Tomogr 1987; 11: 1031–1034.
27. Rosenbaum R, Hoffsten PE, Stanley RJ, et al. Use of computerized tomography to diagnose complications of percutaneous renal biopsy. Kidney Int 1978; 14: 87–92.
28. Trajceska L, Severova-Andreevska G, Dzekova-Vidimliski P, et al. Complications and Risks of Percutaneous Renal Biopsy. Open Access Maced J Med Sci 2019; 7: 992–995.
29. Šimunov B, Guňjača M, Čingel B, et al. Safety of Outpatient Kidney Biopsies. Nephron 2018; 138: 275–279.
30. Korbet SM, Volpini KC and Whittier WL. Percutaneous renal biopsy of native kidneys: a single-center experience of 1,055 biopsies. *Am J Nephrol* 2014; 39: 153–162.

31. Roccatello D, Sciascia S, Rossi D, et al. Outpatient percutaneous native renal biopsy: safety profile in a large monocentric cohort. *BMJ Open* 2017; 7: e015243.

32. Tøndel C, Vikse BE, Bostad L, et al. Safety and complications of percutaneous kidney biopsies in 715 children and 8573 adults in Norway 1988–2010. *Clin J Am Soc Nephrol* 2012; 7: 1591–1597.

33. Azmat R, Siddiqui AB, Khan MTR, et al. Bleeding complications post ultrasound guided renal biopsy – A single centre experience from Pakistan. *Ann Med Surg (Lond)* 2017; 21: 85–88.

34. Esposito V, Mazzon G, Baiardi P, et al. Safety and adequacy of percutaneous kidney biopsy performed by nephrology trainees. *BMC Nephrol* 2018; 19: 14.

35. Lees JS, McQuarrie EP, Mordi N, et al. Risk factors for bleeding complications after nephrologist-performed native renal biopsy. *Clin Kidney J* 2017; 10: 573–577.